NeuroSigma has signed a contract with the University of California, Los Angeles to fund a paediatric trial to investigate a non-invasive, external trigeminal nerve stimulation as a treatment for attention deficit hyperactivity disorder (ADHD).

The open-label Phase I clinical study will involve ten children with the disorder.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Previous clinical studies have shown that external trigeminal nerve stimulation is well tolerated, and that the low-energy stimulus is confined to the soft tissues of the forehead and does not penetrate into the brain.

NeuroSigma president and CEO Leon Ekchian said that the company’s non-invasive external trigeminal nerve stimulation therapy may help to treat ADHD without causing side effects.

The company expects to initiate the trial next month.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now